(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 773.9MM | +4% |
Gross Profit | 431.4MM | +4% |
Cost Of Revenue | 342.5MM | +4% |
Operating Income | 82.5MM | -50% |
Operating Expenses | 348.9MM | - |
Net Income | 31.1MM | -77% |
R&D | 35.9MM | -5% |
G&A | 260.7MM | +22% |
Interest Expense | 25.8MM | +11% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Investing in stocks inevitably means buying into some companies that perform poorly. But the last three years have been...
WAYNE, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its first quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, May 2, 2024. To participate in the conference call, please utilize this link to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, teleflex.com. An audio replay of the call will be availab
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
Nearly 335,000 devices were recalled due to safety issues, which may cause damage to blood vessel walls, artery blockage or death.
WAYNE, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the upcoming full market release of the Advanced Tissue Control (ATC) feature on its unified UroLift™ 2 System platform designed for the treatment of benign prostatic hyperplasia (BPH) symptoms in men with all prostate types up to 100g. The UroLift™ 2 System with Advanced Tissue Control (UroLift™ 2 ATC) has received FDA clearance, marking a significa
Teleflex commits to reach net-zero greenhouse gas emissions across its value chain by 2050.WAYNE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced its near- and long-term climate change targets have been validated by the Science Based Targets initiative (SBTi). The announcement comes ahead of the company’s release of its 2023 Global Impact Report, which will be published in May 2024. Teleflex has respond
Key Insights The projected fair value for Teleflex is US$354 based on 2 Stage Free Cash Flow to Equity Teleflex's...
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Unveiling the Strengths and Challenges: A Deep Dive into Teleflex Inc (TFX) SWOT Analysis
Teleflex Incorporated (NYSE:TFX) Q4 2023 Earnings Call Transcript February 22, 2024 Teleflex Incorporated beats earnings expectations. Reported EPS is $3.38, expectations were $3.26. Teleflex Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome […]